Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
April 2, 2008
An unmet need still unmet, tough luck for Pfizer
Analysis of: Pfizer Ends Clinical Trial Of Melanoma Treatment | online.wsj.com
Author: GLG Expert Contributor
Drug (monoclonal ab?) failed in a phase III trial vs chemotherapy (not particularly effective.)
April 1, 2008
Amgen, Well at least they have Aranesp. (Whoops!)
Analysis of: Unexpected Toxicity with Panitumumab Plus Chemotherapy-Bevacizumab Combo in Colorectal Cancer | www.oncology-times.com
Author: GLG Expert Contributor
Vectibix's undue toxicity without obvious benefits punctures Amgen's hope of finding a first or even second line use for this EGFR directed monoclonal antibody.
April 1, 2008
Implications of mechanism's of action? Who cares if it works!
Analysis of: OXiGENE Begins Phase II NSCLC Trial of ZYBRESTAT(TM) in Combination with Bevacizumab and Chemotherapy | www.pipelinereview.com
Author: GLG Expert Contributor
OXiGENE, Inc's., ZYBRESTAT(TM) (fosbretabulin), a vascular disrupting agent (?) is being given with Taxol/Carboplatin (T/C) in a randomized Phase II study. Soooo T/C with or without ZYBRESTAT.
March 31, 2008
Well at least they have Procrit (Whoops!)
Analysis of: Cancer risk seen with J&J foot gel: FDA | uk.reuters.com
Author: GLG Expert Contributor
 "A Johnson & Johnson foot gel used by diabetics may increase the risk of cancer and death, U.S. health officials said on Thursday in announcing an investigation into the issue."
March 31, 2008
New Therapy for Hormone Refractory Prostate CA. Maybe!!!
Analysis of: Oxford BioMedica Report Encouraging New Phase II Trial Results With TroVax(R) in Prostate Cancer | www.pipelinereview.com
Author: GLG Expert Contributor
Phase II results ++
March 28, 2008
Can I eat until my IQ drops to 120.......?
Analysis of: Study Ties Belly Fat to Dementia | online.wsj.com
Author: GLG Expert Contributor
"Belly Fat" in middle age can be associated with the development of dementia as one ages.
March 27, 2008
CT scanning to detect early lung cancers? Flawed due to ethical concerns
Analysis of: Cigarette Company Paid for Lung Cancer Study | www.nytimes.com
Author: GLG Expert Contributor
Support from a cigarette manufacturer raises questions as to the conclusions from this study which says early detection by repetitive CT's can improve cancer cure rates by early detection. (making smoking safer?)
March 25, 2008
Overuse of Lupron & Zoladex in "early" Prostate Carcinoma?
Analysis of: Prostate-Cancer Treatment Questioned | online.wsj.com
Author: GLG Expert Contributor
Hormone blocking therapy is added to radiation, unnecessarily, in early prostate cancer patients. The result in early stage patients is unnecessary side effects and reduced quality of life. Go figure.
March 24, 2008
OK, now that we know why how can we prevent the reactions to increase utilization of BMS & Imclone's Erbitux?
Analysis of: Researchers Find Cause of Severe Allergic Reaction to Cancer Drug | pharmalive.com
Author: GLG Expert Contributor
Antibodies have been identified that explain allergic reactions that can terminate it's use in individuals who "react."
March 24, 2008
GSK has a monoclonal antibody (Mepolizumab) that can treat patients with "hypereosinophilia.)
Analysis of: Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab | content.nejm.org
Author: GLG Expert Contributor
This exceedingly rare condition produces organ damage due to infiltration of blood eosinophils. Steroids are the only effective therapy in the non myeloproliferative subset of patients, so for the chosen few this drug will be invaluable.

Previous Page : 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 Next121 to 130 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440